Crystalline form of N-methyl-N-((3R,4R)-4-methyl-1-benzyl-3-piperidyl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine

A -4-, 3-D technology, applied in the field of crystallization and preparation of intermediates, can solve the problems of unfavorable industrialization and commercial sales, poor stability, and low purity, and achieve simple and reliable preparation methods, good stability, and high purity high effect
CN105294698AInactive Publication Date: 2016-02-03SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES
1 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES
Publication Date
2016-02-03
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a Tofacitinib midbody, i.e. a new crystalline form of N-methyl-N-((3R,4R)-4-methyl-1-benzyl-3-piperidyl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine, a preparation method thereof, and a method of preparing Tofacitinib by using a midbody of the crystal form. The midbody of the crystal form has the advantages of high purity, good stability, simple preparation, easy production and sales.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention involves the crystallization, preparation method of a drug intermediate, and its purpose in preparing the Telobitinib, which involves the crystallization and preparation methods of the intermediate of a Tasitinib. Background technique Background technique

[0002] Tofacitinib is a new type of oral JAK pathogenesis developed by Pfizer.Unlike most other RA therapy drugs, which are mainly based on extracellular targets, the Toffetu is the core part of the cytokine network with intracellular signal transitional pathways.Tofacitinib's inhibitory intensity of Jak3 is 5 to 100 times the Jak1 and Jak2.Toffubo is the first-in-in-classdrug for developing rheumatoid arthritis therapy. FDA approved the JAK inhibitor TOFACITINIB on November 6, 2012 for the treatment of adult activity during the treatment of adults and alima butterfliesPatients with poor response (MTX) patients with poor reactions.FDA said that patients with medium to severe rheumatoid a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More